ClinicalTrials.gg

How we know

Every link on this study, and who decided it

The study on the left, the conditions and drugs this site links it to, and on each link the judgments that made or checked it, by day and by judge. The top row is the record itself: each new version seen since tracking began. Dashed lines are links the registry record does not make itself. Select a link to see everything judged on it, or a mark for one decision with its reason and evidence.

Why Precursor Cell Lymphoblastic Leukemia-Lymphoma is on this study

  • ClinicalTrials.gov files the study under Precursor Cell Lymphoblastic Leukemia-Lymphoma.
  • GPT-6 Astra (Medium) judged the term too narrow: the study covers more. Oct 20 (day only)
  • It is the study's main condition, by the main-condition rule: the study is compared with others under Precursor Cell Lymphoblastic Leukemia-Lymphoma.
8 links0 made here, not in the record7 judgments2 judges (the rules as one: Rule based)1 record change seen
GPT-6 Astra (Medium)Rule basedRecord updated on ClinicalTrials.gov
Oct 19Oct 26Nov 2Nov 9Nov 16Nov 23TodayNCT06195891Orca-T FollowingChemotherapy and TotalMarrow and LymphoidIrradiation for theTreatment of Acute MyeloidLeukemia, AcuteLymphoblastic Leukemia orCity of Hope Medical CenterPhase 1 · suspendedRECORDThe record itselfVersions seen nightly since Sep 25, 2…›Oct 15 · ClinicalTrials.gov record · Version of 2026-10-15Version of 2026-10-15CONDITIONSPrecursor Cell Lymphoblasti…The registry's MeSH filing›Oct 20 · GPT-6 Astra (Medium) · Broader: Hematologic NeoplasmsAs of now · Rule based · Main conditionMain conditionLeukemia, Myeloid, AcuteThe registry's MeSH filing›No judgment recorded. Shown as the registry files it.Myelodysplastic SyndromesThe registry's MeSH filing›No judgment recorded. Shown as the registry files it.DRUGSFludarabineIntervention entry›Nov 18 · Rule based · BackgroundBackgroundMelphalanIntervention entry›Nov 18 · Rule based · BackgroundBackgroundPartially Engineered T-regu…Intervention entry›Nov 18 · Rule based · TestedTestedTacrolimusIntervention entry›Nov 18 · Rule based · BackgroundBackgroundThiotepaIntervention entry›Nov 18 · Rule based · BackgroundBackground

Times are in your time zone; a day marked “day only” kept no time. The graph scrolls sideways on a narrow screen; every mark is also in the list below.

All judgments on this study

WhenLinkJudgeDecisionState
1 version of the record seen on ClinicalTrials.gov, Oct 15 · changes seen, not judgments
Oct 20Precursor Cell Lymphoblastic Leukemia-LymphomaGPT-6 Astra (Medium)Broader: Hematologic NeoplasmsCurrent
Nov 18FludarabineRule based · role ruleBackgroundCurrent
Nov 18MelphalanRule based · role ruleBackgroundCurrent
Nov 18Partially Engineered T-regulatory Cell Donor Graft TRGFT-201Rule based · role ruleTestedCurrent
Nov 18TacrolimusRule based · role ruleBackgroundCurrent
Nov 18ThiotepaRule based · role ruleBackgroundCurrent
As of nowPrecursor Cell Lymphoblastic Leukemia-LymphomaRule based · main-condition ruleMain conditionCurrent

The rules, in plain words

“Rule based” means one of these decided, not a model or a person. Each runs every night over every study.

Which drugs a study tests

Reads each treatment the study lists and the arms it is in. A drug only in the experimental arm is tested. A drug in every arm while something else changes between the arms is given beside it. A drug only in the control arm is the comparator. Placebo, procedures and usual care are known by name.

Where the whole record has been read, that reading's answer replaces the rule's.

What a study is mainly about

Starts from the first condition ClinicalTrials.gov files the study under. It moves to a narrower one only when the study's own title or listed conditions name it, and sets aside terms the registry often files by mistake. A study open to many cancers is not placed under one of them unless its title names it.

Checked against studies judged one by one; the study page says when it differs from the registry.